MbrlCatalogueTitleDetail

Do you wish to reserve the book?
Sustained Regression of Tumors upon MYC Inactivation Requires P53 or Thrombospondin-1 to Reverse the Angiogenic Switch
Sustained Regression of Tumors upon MYC Inactivation Requires P53 or Thrombospondin-1 to Reverse the Angiogenic Switch
Hey, we have placed the reservation for you!
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Sustained Regression of Tumors upon MYC Inactivation Requires P53 or Thrombospondin-1 to Reverse the Angiogenic Switch
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Title added to your shelf!
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Sustained Regression of Tumors upon MYC Inactivation Requires P53 or Thrombospondin-1 to Reverse the Angiogenic Switch
Sustained Regression of Tumors upon MYC Inactivation Requires P53 or Thrombospondin-1 to Reverse the Angiogenic Switch

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
How would you like to get it?
We have requested the book for you! Sorry the robot delivery is not available at the moment
We have requested the book for you!
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Sustained Regression of Tumors upon MYC Inactivation Requires P53 or Thrombospondin-1 to Reverse the Angiogenic Switch
Sustained Regression of Tumors upon MYC Inactivation Requires P53 or Thrombospondin-1 to Reverse the Angiogenic Switch
Journal Article

Sustained Regression of Tumors upon MYC Inactivation Requires P53 or Thrombospondin-1 to Reverse the Angiogenic Switch

2006
Request Book From Autostore and Choose the Collection Method
Overview
The targeted inactivation of oncogenes offers a rational therapeutic approach for the treatment of cancer. However, the therapeutic inactivation of a single oncogene has been associated with tumor recurrence. Therefore, it is necessary to develop strategies to override mechanisms of tumor escape from oncogene dependence. We report here that the targeted inactivation of MYC is sufficient to induce sustained regression of hematopoietic tumors in transgenic mice, except in tumors that had lost p53 function. p53 negative tumors were unable to be completely eliminated, as demonstrated by the kinetics of tumor cell elimination revealed by bioluminescence imaging. Histological examination revealed that upon MYC inactivation, the loss of p53 led to a deficiency in thrombospondin-1 (TSP-1) expression, a potent antiangiogenic protein, and the subsequent inability to shut off angiogenesis. Restoration of p53 expression in these tumors re-established TSP-1 expression. This permitted the suppression of angiogenesis and subsequent sustained tumor regression upon MYC inactivation. Similarly, the restoration of TSP-1 alone in p53 negative tumors resulted in the shut down of angiogenesis and led to sustained tumor regression upon MYC inactivation. Hence, the complete regression of tumor mass driven by inactivation of the MYC oncogene requires the p53-dependent induction of TSP-1 and the shut down of angiogenesis. Notably, overexpression of TSP-1 alone did not influence tumor growth. Therefore, the combined inactivation of oncogenes and angiogenesis may be a more clinically effective treatment of cancer. We conclude that angiogenesis is an essential component of oncogene addiction.